tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sheiner PA et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. 1994 Transplantation pmid:7513099
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
First MR and Fitzsimmons WE New drugs to improve transplant outcomes. 2004 Transplantation pmid:15201693
Migita K et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. 1999 Transplantation pmid:10532544
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Waldman WJ et al. Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. 2001 Transplantation pmid:11707749
Ravindran VK et al. Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. 2009 Transplantation pmid:19543067
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Sheiner PA et al. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. 1997 Transplantation pmid:9355846
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
Reding R et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. 1994 Transplantation pmid:7507272
Storb R et al. FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. 1993 Transplantation pmid:7692635
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Reddy KS et al. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. 2000 Transplantation pmid:10653379
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Jevnikar A et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. 2008 Transplantation pmid:18852662
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Naesens M and Sarwal MM Monitoring calcineurin inhibitor therapy: localizing the moving target. 2010 Transplantation pmid:20458272
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
McLaren A Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. 2003 Transplantation pmid:14705621
Amundsen R et al. Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. 2009 Transplantation pmid:19384170
Jun KR et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. 2009 Transplantation pmid:19384171
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Roberts CA et al. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. 2002 Transplantation pmid:12364862
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Hu H et al. Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. 2003 Transplantation pmid:12698107
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Rezeig MA et al. Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. 1997 Transplantation pmid:9175820
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575
Talento A et al. A single administration of LFA-1 antibody confers prolonged allograft survival. 1993 Transplantation pmid:7679531
Mor E et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7513098
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Fougeray S et al. Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. 2011 Transplant. Proc. pmid:22099811
Tang J et al. Cytokine Profile in Calcineurin Inhibitor-Induced Chronic Nephrotoxicity in Chinese Liver Transplant Recipients. 2016 Transplant. Proc. pmid:27788813
Neylan JF Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636551
Tanabe K et al. ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11119903
Elmer DS et al. Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts. 1998 Transplant. Proc. pmid:9532159
Berman M et al. Lipid metabolism and immunosuppressive therapy in heart transplant recipients. 2003 Transplant. Proc. pmid:12644091
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Yamaguchi M et al. FK 506 significantly improves transferred insulin gene expression in total pancreatectomized dogs. 2000 Transplant. Proc. pmid:11120255
Morales JM et al. Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. 1999 Transplant. Proc. pmid:10576051
Mano A et al. Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. 2009 Transplant. Proc. pmid:19917396
Lampreabe I et al. Toward personalized medicine in renal transplantation. 2010 Transplant. Proc. pmid:20970553
Sato K et al. Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy. 2009 Jan-Feb Transplant. Proc. pmid:19249521
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Su MS and Semerjian A Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner. 1991 Transplant. Proc. pmid:1721310
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Suga A et al. Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. 2003 Transplant. Proc. pmid:12591391
Koefoed-Nielsen PB et al. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. 2005 Transplant. Proc. pmid:15919449
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Uemoto S et al. Experience with FK 506 in living related donor liver transplantation. 1991 Transplant. Proc. pmid:1721342
Aguirrezabalaga J et al. Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. 2002 Transplant. Proc. pmid:12176480
Gerauer K et al. Long-term cardiac allograft survival in mice treated with malononitrilamide 715. 1998 Transplant. Proc. pmid:9865349
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Parada MT et al. Everolimus in lung transplantation in Chile. 2010 Jan-Feb Transplant. Proc. pmid:20172343
Weimer R et al. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. 2002 Transplant. Proc. pmid:12270445
Oltean M et al. FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. 2005 Transplant. Proc. pmid:15919508
Jordan ML et al. Five-year experience with tacrolimus rescue for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123009
Fahlke J et al. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study. 2002 Transplant. Proc. pmid:12072328
Yamada T et al. Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8907927
Uchida K et al. Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in Japan. 2002 Transplant. Proc. pmid:12176503
Calia R et al. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. 2011 Transplant. Proc. pmid:21620041
Nakata S et al. Immunosuppressive mechanisms of deoxymethylspergualin and FK 506 on in vitro cytotoxic T lymphocytes. 1994 Transplant. Proc. pmid:7520613
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721374
Christians U et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. 1991 Transplant. Proc. pmid:1703358
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Grochowicz PM et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. 1997 Feb-Mar Transplant. Proc. pmid:9123296
Gerbase MW et al. Low doses of mycophenolate mofetil with low doses of tacrolimus prevent acute rejection and long-term function loss after lung transplantation. 2001 Transplant. Proc. pmid:11377481
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Sifontis NM et al. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. 2002 Transplant. Proc. pmid:12176554
Lee PC et al. Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? 2012 Transplant. Proc. pmid:22310598
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Berloco P et al. Tacrolimus as cornerstone immunosuppressant in kidney transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267161
Shi Y et al. Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplant. Proc. pmid:28104150
Alkhunaizi AM et al. Breast fibroadenomas in renal transplant recipients. 2004 Jul-Aug Transplant. Proc. pmid:15350492
Lauro A et al. Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? 2005 Transplant. Proc. pmid:15964382
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Doesch AO et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. 2010 Transplant. Proc. pmid:21168673
Lim SM et al. Heterotopic heart transplantation in the rat receiving FK-506. 1987 Transplant. Proc. pmid:2445080
Mohamed MA et al. TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267336
Alvarez-Elías AC et al. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children. 2016 Transplant. Proc. pmid:27110018
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Simmons RL and Wang SC New horizons in immunosuppression. 1991 Transplant. Proc. pmid:1714645
Tanabe K et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. 1998 Transplant. Proc. pmid:9636497